Business
Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease
Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease\n\n\n\n\n\nAmarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease\nPatent issuance will provide intellectual property protection in China for protein therapy, gene therapy and cell therapy applications of MANF\nPR Newswire\nSAN FRANCISCO, January 29, 2016\n\n\n\nSAN FRANCISCO, January 29, 2016 /PRNewswire/ --\n\nAmarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the issuance of  Chinese patent number ZL2009801163060 entitled \"Neurodegenerative Disorders\" covering the use of MANF for the treatment of Parkinson's disease and other neurodegenerative conditions. The claims issued extend patent coverage for MANF protein therapy, gene therapy and cell therapy applications into 2029.\n\n\"The Chinese market represents a potential significant market opportunity for Amarantus,\" said Gerald E. Commissiong, President & CEO of Amarantus. \"MANF has demonstrated proof of concept in various efficacy and delivery animal models of Parkinson's disease. Going forward, the Company will look to partner the development of MANF with a group in China capable of bringing this technology to market in that region.\"\n\nThe key claim issued in this patent is \"Use of MANF for the manufacture of a medicament for administration to the substantia nigra region of the brain for treating Parkinson's disease.\" The substantia nigra is a key area of the brain where dopamine producing neurons degenerate in Parkinson's disease. Additional claims covering combinations of MANF and other therapeutic moieties were also granted. This patent adds to Amarantus' extensive international intellectual property portfolio covering compositions of matter, methods of use and formulations for MANF.\n\nAbout Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) \n\nMANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF a...